California Public Employees Retirement System Has $5.29 Million Stock Holdings in ArQule, Inc. (NASDAQ:ARQL)

California Public Employees Retirement System increased its holdings in shares of ArQule, Inc. (NASDAQ:ARQL) by 11.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,797 shares of the biotechnology company’s stock after buying an additional 28,000 shares during the period. California Public Employees Retirement System owned about 0.22% of ArQule worth $5,285,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Syquant Capital Sas bought a new position in ArQule during the 4th quarter worth approximately $12,371,000. Squarepoint Ops LLC raised its holdings in ArQule by 438.5% during the 3rd quarter. Squarepoint Ops LLC now owns 355,717 shares of the biotechnology company’s stock worth $2,550,000 after purchasing an additional 289,663 shares during the last quarter. Metropolitan Life Insurance Co NY raised its holdings in ArQule by 7.8% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 34,929 shares of the biotechnology company’s stock worth $250,000 after purchasing an additional 2,526 shares during the last quarter. California State Teachers Retirement System raised its holdings in ArQule by 11.3% during the 3rd quarter. California State Teachers Retirement System now owns 174,817 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 17,816 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in ArQule by 4.4% during the 3rd quarter. Rhumbline Advisers now owns 148,825 shares of the biotechnology company’s stock worth $1,067,000 after purchasing an additional 6,229 shares during the last quarter. Institutional investors and hedge funds own 74.63% of the company’s stock.

Several research analysts have issued reports on ARQL shares. Needham & Company LLC lowered shares of ArQule from a “buy” rating to a “hold” rating in a report on Monday, December 9th. ValuEngine lowered shares of ArQule from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. BidaskClub lowered shares of ArQule from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 16th. Cantor Fitzgerald lowered shares of ArQule from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $16.00 to $20.00 in a report on Tuesday, December 10th. Finally, Zacks Investment Research lowered shares of ArQule from a “buy” rating to a “hold” rating in a report on Thursday, October 31st. Eight equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $16.78.

NASDAQ:ARQL opened at $20.00 on Friday. The company has a fifty day moving average of $20.00 and a 200-day moving average of $12.63. The firm has a market capitalization of $2.42 billion, a P/E ratio of -125.00 and a beta of 2.49. The company has a quick ratio of 8.27, a current ratio of 8.27 and a debt-to-equity ratio of 0.08. ArQule, Inc. has a twelve month low of $3.15 and a twelve month high of $20.45.

About ArQule

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.

Featured Story: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.